A Phase 2 interventional study of Xilonix in Pyoderma Gangrenosum, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by Janssen Research & Development, LLC · Phase 2, Interventional, and Treatment
The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.
XBiotech owned bermekimab and sponsored and completed study prior to Dec 30, 2019.
Exclusion Criteria:
Open label-Xilonix
Biological: Xilonix
IV
Change in Physician's Wound Assessment & Patient's Global Assessment
Time frame: 28 days
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC